| Literature DB >> 35426008 |
Jenny Newlon1, Katy Ellis Hilts2, Victoria Champion3, Karen Suchanek Hudmon4.
Abstract
Interprofessional strategies for promoting tobacco cessation lead to enhanced quit rates among patients; however, current approaches might not effectively support patients with their quit attempts after they are discharged from the hospital. This paper explores opportunities for interprofessional collaboration between health system-based providers and community pharmacists, as one proposed approach to bridging tobacco cessation services during transitions of care. Suggested strategies include (1) increasing other healthcare professionals' awareness of legislative advances that permit pharmacists to prescribe cessation medications in some states, and (2) encouraging bi-directional communication between health system-based and community-based providers, especially via integrated electronic health records. Community pharmacists can offer a convenient solution to obtain the post-discharge medication and counseling support that patients need to increase their chances of quitting for good. Additional steps are discussed to improve broadscale capacity of this service being provided in community pharmacies.Entities:
Mesh:
Year: 2022 PMID: 35426008 PMCID: PMC9009499 DOI: 10.1007/s11606-022-07546-w
Source DB: PubMed Journal: J Gen Intern Med ISSN: 0884-8734 Impact factor: 6.473
States with Prescriptive Authority for Cessation Medications (April 2021)
| State | Non-prescription nicotine medications* | Prescription nicotine medications† | Varenicline and bupropion SR‡ | Prescribing implemented |
|---|---|---|---|---|
| Arizona | ✓ | ✓ | ✓ | 2017 |
| Arkansas | ✓ | ✓ | 2020 | |
| California | ✓ | ✓ | 2016 | |
| Colorado | ✓ | ✓ | ✓ | 2017 |
| Idaho | ✓ | ✓ | ✓ | 2017 |
| Indiana | ✓ | ✓ | ✓ | 2019 |
| Iowa | ✓ | ✓ | 2020 | |
| Maine | ✓ | 2017 | ||
| Missouri | ✓ | ✓ | 2019 | |
| Minnesota | ✓ | ✓ | 2020 | |
| New Mexico | ✓ | ✓ | ✓ | 2004 |
| Oregon | ✓ | ✓ | ✓ | 2020 |
| Vermont | ✓ | ✓ | ✓ | 2021 |
| West Virginia | ✓ | ✓ | 2019 |
*Nicotine transdermal patch, gum, and lozenge
†Nicotine nasal spray and inhaler
‡Sustained-release (the only bupropion formulation with an FDA indication for smoking cessation)
Figure 1Including community pharmacists in tobacco cessation services during transitions of care.